Updated results of a phase 1 study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC; SGNS40-001).

Authors:

Abstract
No abstract available
Funding Information
  • Seagen Inc.
  • Merck Sharp & Dohme Corp